Madison Fichtner, Author at EverGlade Consulting

Madison Fichtner

EverGlade Consulting

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors

By Madison Fichtner, Operations Manager and Eric Jia-Sobota, Founder  The Defense Advanced Research Projects Agency is hosting an Industry Day for the B-SAFE (Broad-Spectrum Antagonists for Editors) program on June 28, 2024, in Arlington, VA, with a webinar option available. This event is pivotal for those in the science and technology communities, including industry, academia, […]

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors Read More »

EverGlade Consulting

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease

At EverGlade Consulting, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we’re excited to inform you about a new Request for Applications (RFA) from the National Institutes of Health (NIH): RFA-HG-24-004.

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease Read More »

EverGlade Consulting

EverGlade Funding Alert – BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D 

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats. 

EverGlade Funding Alert – BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D  Read More »

Scroll to Top